September 9, 2016—A new insurance industry study shows that almost half of the time orphan drugs are used for non-orphan indications. Not only that, it found that orphan drugs with the highest rates of non-orphan use are seeing the largest price increases. Such findings raise the question whether drug companies are gaming the orphan drug system to maximize its benefits while at the same time minimizing their exposure to 340B pricing.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)